ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Micelle nanogel-based drug delivery system for lutein in ocular administration.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoparticle-mediated targeted delivery of lutein for retinal protection: emerging strategies in ocular drug targeting.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nanoparticle-Mediated Lutein Delivery for Diabetic Retinopathy: From Blood-Retinal Barrier Crossing to Neurovascular Unit Protection.International journal of nanomedicine · 2026Review
- From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics.Materials today. Bio · 2025Review
- Biodegradable sustained-release microneedle patch loaded with clindamycin hydrochloride: a breakthrough in acne management.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Recent studies have demonstrated that antioxidants like lutein considerably lower the prevalence of age-related macular degeneration (AMD), which has been connected to blindness in numerous older adults. By halting oxidation, antioxidants reduce the damage that free radicals do. However, the short residence time, low stability, and poor solubility of lutein limit their ocular bioavailability following topical application. This study aimed to develop and characterize a micelle nanogel formulation for the ocular delivery of lutein. The micelle nanogel delivery system suggests a novel therapeutic strategy for administering ocular drugs due to its longer retention on the ocular surface, improved corneal permeability, and lowering the need for frequent administration. We developed a nanosized lutein micelle and incorporated it into a gel base to increase the solubility and ocular permeability. The micelle nanoformulation underwent evaluations like mean particle size, entrapment efficiency (EE), zeta potential, in vitro release investigations, ex vivo permeation tests, cell line studies, and Hen's egg test chorioallantoic membrane (HET-CAM). This nanoformulation exhibited favorable particle size (205.2 ± 15.36 nm), PDI (0.3 ± 0.20), and zeta potential (- 14.2 to + 11.3 mV) with 84.5 ± 1.75% entrapment efficiency. Fourier transform infrared spectroscopy confirmed compatibility, while TEM showed nanoscale spherical structures. F4 demonstrated effective corneal penetration, enhanced fibroblast viability, antioxidant activity (IC
Indexed as
Identifiers
40019526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.